NASDAQ:SAVA Cassava Sciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $26.51 -1.61 (-5.73%) (As of 07/1/2022 05:44 PM ET) Add Compare Share Today's Range$25.82▼$28.7450-Day Range$17.22▼$30.8552-Week Range$15.72▼$146.16Volume754,654 shsAverage Volume1.64 million shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice Target$124.25 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Cassava Sciences Stock Forecast (MarketRank)Analyst RatingHold2.40 Rating ScoreUpside/Downside368.7% Upside$124.25 Price TargetShort InterestHealthy27.37% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.57Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.75) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.85 out of 5 starsMedical Sector755th out of 1,429 stocksPharmaceutical Preparations Industry363rd out of 682 stocks 3.2 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $124.25, Cassava Sciences has a forecasted upside of 368.7% from its current price of $26.51.Amount of Analyst CoverageCassava Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted27.37% of the outstanding shares of Cassava Sciences have been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 4.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 1.4 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cassava Sciences this week, compared to 9 articles on an average week.Search InterestOnly 36 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.MarketBeat FollowsOnly 20 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.10% of the stock of Cassava Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.01% of the stock of Cassava Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to grow in the coming year, from ($1.75) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -22.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -22.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Cassava Sciences (NASDAQ:SAVA)Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Read More SAVA Stock News HeadlinesJune 24, 2022 | americanbankingnews.comCassava Sciences (NASDAQ:SAVA) Trading 8.2% Higher June 23, 2022 | nasdaq.comSAVA August 5th Options Begin TradingJune 16, 2022 | finance.yahoo.comCassava Sciences, Inc. (SAVA) Stock Moves -1.38%: What You Should KnowJune 6, 2022 | markets.businessinsider.com5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow RiseJune 2, 2022 | finance.yahoo.comThe 7 Best Meme Stocks to Buy NowJune 1, 2022 | seekingalpha.comCassava Sciences reverses gains as journal retracts Alzheimer’s paperMay 31, 2022 | seekingalpha.comCassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear DebateMay 31, 2022 | seekingalpha.comCassava Sciences rallies most since NovemberMay 27, 2022 | benzinga.comCassava Sciences Whale Trades For May 27May 25, 2022 | seekingalpha.comINmune Bio: Possibly The Once In A Lifetime DipMay 16, 2022 | apnews.comBragar Eagel & Squire, P.C. Is Investigating Cassava, Dentsply Sirona, IonQ, and Singularity Future and Encourages Investors to Contact the FirmMay 12, 2022 | uk.investing.comHow Is The Market Feeling About Cassava Sciences?May 11, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating Verra, Cassava, Dentsply Sirona, and Axsome and Encourages Investors to Contact the FirmSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees24Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/01/2022Next Earnings (Estimated)8/02/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$124.25 High Stock Price Forecast$215.00 Low Stock Price Forecast$58.00 Forecasted Upside/Downside+368.7%Consensus RatingHold Rating Score (0-4)2.4 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-17.93% Return on Assets-17.40% Debt Debt-to-Equity RatioN/A Current Ratio32.73 Quick Ratio32.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.35 per share Price / Book4.17Miscellaneous Outstanding Shares40,081,000Free Float36,033,000Market Cap$1.06 billion OptionableNot Optionable Beta0.92 Cassava Sciences Frequently Asked Questions Should I buy or sell Cassava Sciences stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Cassava Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares. View analyst ratings for Cassava Sciences or view top-rated stocks. What is Cassava Sciences' stock price forecast for 2022? 5 Wall Street research analysts have issued 1-year target prices for Cassava Sciences' shares. Their SAVA stock forecasts range from $58.00 to $215.00. On average, they predict Cassava Sciences' share price to reach $124.25 in the next twelve months. This suggests a possible upside of 368.7% from the stock's current price. View analysts' price targets for Cassava Sciences or view top-rated stocks among Wall Street analysts. How has Cassava Sciences' stock performed in 2022? Cassava Sciences' stock was trading at $43.70 at the beginning of the year. Since then, SAVA shares have decreased by 39.3% and is now trading at $26.51. View the best growth stocks for 2022 here. When is Cassava Sciences' next earnings date? Cassava Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Cassava Sciences. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings data on Thursday, May, 5th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.02. View Cassava Sciences' earnings history. When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work? Cassava Sciences's stock reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split. Who are Cassava Sciences' key executives? Cassava Sciences' management team includes the following people: Mr. Remi Barbier, Founder, Chairman, Pres & CEO (Age 62, Pay $1.74M)Mr. Eric J. Schoen, Chief Financial Officer (Age 54, Pay $776.93k)Dr. Nadav Friedmann M.D., Ph.D., Chief Medical Officer & Director (Age 79, Pay $765k)Dr. James W. Kupiec M.D., Chief Clinical Devel. OfficerDr. George Thornton, Sr. VP of TechnologyMr. Michael Zamloot, Sr. VP of Technical OperationsDr. Lindsay H. Burns Ph.D., Sr. VP of Neuroscience Who are some of Cassava Sciences' key competitors? Some companies that are related to Cassava Sciences include Evotec (EVTCY), Mirati Therapeutics (MRTX), Cerevel Therapeutics (CERE), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Amicus Therapeutics (FOLD), Prestige Consumer Healthcare (PBH) and PTC Therapeutics (PTCT). View all of SAVA's competitors. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA). What is Cassava Sciences' stock symbol? Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA." How do I buy shares of Cassava Sciences? Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cassava Sciences' stock price today? One share of SAVA stock can currently be purchased for approximately $26.51. How much money does Cassava Sciences make? Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $1.06 billion. The company earns $-32.38 million in net income (profit) each year or ($1.16) on an earnings per share basis. How many employees does Cassava Sciences have? Cassava Sciences employs 24 workers across the globe. How can I contact Cassava Sciences? Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for Cassava Sciences is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at [email protected], or via fax at 512-501-0414. This page (NASDAQ:SAVA) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here